Cargando…

Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease

Detalles Bibliográficos
Autores principales:	Mackintosh, John A, Lipman, Marc, Lowe, David M, Renzoni, Elisabetta A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285116/ https://www.ncbi.nlm.nih.gov/pubmed/34274035 http://dx.doi.org/10.1016/S2213-2600(21)00326-X

Ejemplares similares

Immunosuppression and SARS-CoV-2 breakthrough infections
por: Kim, Alfred H J, et al.
Publicado: (2022)

Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022)

Managing waning vaccine protection against SARS-CoV-2 variants
por: Leung, Kathy, et al.
Publicado: (2022)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Have we missed AINything? Acute interstitial nephritis in SARS-CoV-2 infection and vaccination
por: Storrar, Joshua, et al.
Publicado: (2022)

Are smokers protected against SARS-CoV-2 infection (COVID-19)? The origins of the myth
por: van Westen-Lagerweij, Naomi A., et al.
Publicado: (2021)

SARS-CoV-2 evolution and vaccines: cause for concern?
por: Williams, Thomas C, et al.
Publicado: (2021)

Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19
por: Li, Jing-Xin, et al.
Publicado: (2021)

Bell's palsy and SARS-CoV-2 vaccines
por: Ozonoff, Al, et al.
Publicado: (2021)

Optimising SARS-CoV-2 vaccination schedules
por: Belda-Iniesta, Cristobal
Publicado: (2021)

Guillain-Barre syndrome related to SARS-CoV-2 vaccinations
por: Finsterer, Josef, et al.
Publicado: (2022)

Correlates of protection from SARS-CoV-2 infection
por: Krammer, Florian
Publicado: (2021)

SARS-CoV-2 vaccines: fast track versus efficacy
por: Alkandari, Dana, et al.
Publicado: (2021)

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
por: Triccas, James A., et al.
Publicado: (2022)

Telomeres in Interstitial Lung Disease
por: Stock, Carmel J. W., et al.
Publicado: (2021)

Recombinant protein vaccines against SARS-CoV-2
por: Gilbert, Sarah C, et al.
Publicado: (2021)

Stroke after SARS-CoV-2 vaccination: Comment
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Dissecting antibody-mediated protection against SARS-CoV-2
por: Zohar, Tomer, et al.
Publicado: (2020)

SARS-CoV-2: eye protection might be the missing key
por: Coroneo, Minas Theodore, et al.
Publicado: (2021)

Risks of lung transplantation in the SARS-CoV-2 era
por: Meyer, Keith C
Publicado: (2021)

SARS-CoV-2 vaccination and phase 1 cancer clinical trials
por: Yap, Timothy A, et al.
Publicado: (2021)

The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines
por: Shang, Weilong, et al.
Publicado: (2020)

Will SARS-CoV-2 variants of concern affect the promise of vaccines?
por: Gupta, Ravindra K.
Publicado: (2021)

Single-dose SARS-CoV-2 vaccination efficacy in the elderly
por: Prendecki, Maria, et al.
Publicado: (2021)

Balancing risk and benefit of SARS-CoV-2 vaccines in children
por: Levin, Michael, et al.
Publicado: (2022)

SARS-CoV-2 vaccine strategies in kidney transplant recipients
por: Prendecki, Maria, et al.
Publicado: (2023)

Stroke seven hours after SARS-CoV-2 vaccination
por: Fiorini, Ana Claudia, et al.
Publicado: (2023)

Protective immunity after recovery from SARS-CoV-2 infection
por: Kojima, Noah, et al.
Publicado: (2022)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Oxygen in interstitial lung diseases
por: Cordeiro, Ricardo, et al.
Publicado: (2023)

B cells: more than just for antibodies in SARS-CoV-2 vaccine responses
por: Paley, Michael A, et al.
Publicado: (2021)

WHO international standard for SARS-CoV-2 antibodies to determine markers of protection
por: Zhu, Feng, et al.
Publicado: (2022)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine
por: Kennedy, Richard B
Publicado: (2022)

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma
por: Lim, Sean H, et al.
Publicado: (2021)

SARS-CoV-2 and HIV-1 — a tale of two vaccines
por: Haynes, Barton F.
Publicado: (2021)

Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world
por: Garg, Pramod Kumar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rstdvn211cdl4l24r9m9r0ejhl